Leukoencephalopathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 07 Jul 2026 04:03:59 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Leukoencephalopathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Cerebrolysin and Sodium Chloride for Patients with CADASIL https://clinicaltrials.eu/trial/study-on-cerebrolysin-and-sodium-chloride-for-patients-with-cadasil/ Wed, 29 Apr 2026 14:59:17 +0000 https://clinicaltrials.eu/trial/study-on-cerebrolysin-and-sodium-chloride-for-patients-with-cadasil/ This clinical trial is focused on studying a rare genetic condition called , which stands for Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. This condition affects the small blood vessels in the brain, leading to strokes and other brain-related issues. The trial will test the effects of a treatment called , which is a solution for injection, to see if it can help patients with CADASIL. Cerebrolysin is compared to a placebo to evaluate its safety and effectiveness.

The purpose of the study is to assess the overall benefits and risks of using Cerebrolysin in patients who have been genetically confirmed to have CADASIL. Participants in the study will receive either Cerebrolysin or a placebo through intravenous infusion, which means the solution is given directly into a vein. The study will take place over two periods, each lasting several months, and will involve regular assessments of the participants’ cognitive abilities, mood, and brain imaging results.

Throughout the study, participants will be monitored to see how they respond to the treatment. The trial aims to gather important information about how Cerebrolysin affects the brain and overall health of people with CADASIL. This research could provide valuable insights into potential new treatments for this challenging condition.

]]> Study on the Safety and Tolerability of VGL101 for Adults with Adult-Onset Leukoencephalopathy https://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-vgl101-for-adults-with-adult-onset-leukoencephalopathy/ Wed, 29 Apr 2026 14:23:50 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-vgl101-for-adults-with-adult-onset-leukoencephalopathy/ This clinical trial is focused on studying a rare brain disease called Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP). This condition affects the brain’s white matter, which is crucial for transmitting signals in the brain. The study will use a treatment called VGL101, which is given as a solution for injection through a method known as intravenous infusion, meaning it is delivered directly into the bloodstream.

The purpose of the study is to evaluate how safe and tolerable the treatment is for patients with ALSP. Participants in the study will receive either the treatment or a placebo. The study will last for about a year, during which participants will have regular check-ups to monitor their health and any changes in their condition. These check-ups will include various tests, such as blood tests and MRI scans, to observe any effects of the treatment on the brain and overall health.

Throughout the study, researchers will pay close attention to any side effects or adverse reactions to the treatment. The goal is to gather information that could help in understanding how well VGL101 works and how it might be used to help people with ALSP in the future. Participants will be closely monitored to ensure their safety and well-being during the trial period.

]]>